Company intelligence / Profile preview

Embria Health Sciences

Ankeny, Iowa, United Statesembria.com ↗

Ownership: Private
Employees: ~29
Development stage: Other

Overview

Embria Health Sciences has developed EpiCor, an immunogenic yeast-based fermentation product. Clinical studies have shown that EpiCor may reduce the incidence of common cold and flu symptoms in children and decrease nasal congestion associated with allergic rhinitis. The company focuses on science-backed natural ingredients for wellness applications[2][6].

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Live biotherapeutic product therapyNutraceutical
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Embria Health Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Embria Health Sciences.

Explore the full profile